Skip to content

Enliven Therapeutics

US · ELVN #2416 by market cap Listed 1970
46.53 +0.12 +0.26%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 4.09 Expensive vs history 84th percentile
5-year average 2.58 · #359 of 514 in Biotechnology
P/E ratio -28.88 Cheap vs history 19th percentile
5-year average -15.47 · forward -23.55
P/S ratio --
5-year average 0.00

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Enliven Therapeutics (ELVN) 3.42B -27.53 3.90 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value58.64 Economic moatNone UncertaintyHigh

Trading 26.0% below Morningstar's fair value estimate.

Fair value

Enliven Therapeutics Inc receives a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 17% discount to our quantitative fair value estimate of $58.64 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The company's balance sheet increases our estimated fair value. Low leverage mitigates financial risk, potentially boosting a firm's value. For example, the firm's current ratio sits in the top 1% compared with peers globally. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which contributes to our view that shares are undervalued.

Conversely, the firm's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of -2.2%, for example, ranks in the bottom 30% globally. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Enliven Therapeutics discussion 0 comments

Add a comment